van der Werf S, Bradley J, Wimmer E, Studier F W, Dunn J J
Proc Natl Acad Sci U S A. 1986 Apr;83(8):2330-4. doi: 10.1073/pnas.83.8.2330.
Plasmids containing the entire cDNA sequence of poliovirus type 1 (Mahoney strain) under control of a promoter for T7 RNA polymerase have been constructed. Purified T7 RNA polymerase efficiently transcribes the entire poliovirus cDNA in either direction to produce full-length poliovirus RNA [(+)RNA] or its complement [(-)RNA]. The (+)RNA produced initially had 60 nucleotides on the 5' side of the poliovirus RNA sequence, including a string of 18 consecutive guanine residues generated in the original cloning and an additional 626 nucleotides of pBR322 sequence beyond the poly(A) tract at the 3' end. Such RNA, while much more infectious than the plasmid DNA, is only about 0.1% as infectious as RNA isolated from the virus. Subsequently, a T7 promoter was placed only 2 base pairs ahead of the poliovirus sequence, so that T7 RNA polymerase synthesizes poliovirus RNA with only 2 additional guanine residues at the 5' end and no more than seven nucleotides past the poly(A) tract at the 3' end. Such RNA has much higher specific infectivity, about 5% that of RNA isolated from the virus. The ability to make infectious poliovirus RNA efficiently from cloned DNA makes it possible to apply techniques of in vitro mutagenesis to the analysis of poliovirus functions and the construction of novel and perhaps useful derivatives of poliovirus. A source of variant RNAs should also allow detailed study of the synthesis and processing of poliovirus proteins in vitro.
已构建出含有脊髓灰质炎病毒1型(Mahoney株)完整cDNA序列且受T7 RNA聚合酶启动子控制的质粒。纯化的T7 RNA聚合酶能有效地沿任一方向转录脊髓灰质炎病毒的完整cDNA,以产生全长脊髓灰质炎病毒RNA[(+)RNA]或其互补链[(-)RNA]。最初产生的(+)RNA在脊髓灰质炎病毒RNA序列的5'端有60个核苷酸,包括原始克隆中产生的一串18个连续鸟嘌呤残基以及3'端多聚(A)尾之后pBR322序列的另外626个核苷酸。这种RNA虽然比质粒DNA的感染性强得多,但仅约为从病毒中分离出的RNA感染性的0.1%。随后,将一个T7启动子置于脊髓灰质炎病毒序列之前仅2个碱基对处,这样T7 RNA聚合酶合成的脊髓灰质炎病毒RNA在5'端仅带有2个额外的鸟嘌呤残基,在3'端多聚(A)尾之后不超过七个核苷酸。这种RNA具有更高的比感染性,约为从病毒中分离出的RNA的5%。能够从克隆的DNA高效地制备感染性脊髓灰质炎病毒RNA,使得将体外诱变技术应用于脊髓灰质炎病毒功能分析以及构建脊髓灰质炎病毒的新型且可能有用的衍生物成为可能。变异RNA的来源也应允许在体外详细研究脊髓灰质炎病毒蛋白的合成和加工。